medRxiv
June 1, 2026
Erica J. Li, Basmah Mosharraf, Hiba Ali et al.
Background: Psychedelics are emerging as potential management options for chronic musculoskeletal pain due to preliminary evidence of effectiveness and low addictive potential, but patients’ perceptions remain unknown. This study assessed patient perceptions regarding psilocybin for musculoskeletal pain. Methods: We conducted a cross-sectional survey of adults (≥19) with musculoskeletal pain...
BJPsych Open
May 13, 2026
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
Research Square
February 23, 2026
Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al.
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...
BJPsych Open
February 16, 2026
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
1 citation
BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
November 16, 2025
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
preprint
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
Neuroscience & Biobehavioral Reviews
May 9, 2025
Rotem Petranker, Benjamin Tsang, Omer A. Syed
3 citations
Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is associated with many benefits to mood, well-being and health, research in this area is in its early stages and predominantly centered on human applications. In this narrative review, we synthesize the findings from studies investigating the effects...
Journal of Psychoactive Drugs
December 24, 2024
Omer A. Syed, Rotem Petranker, Emily C. Fewster et al.
3 citations
Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little research has examined the preferences surrounding the source of psychedelic substances. In an anonymous online survey, we collected data from 6,379 consumers of 11 different psychedelic substances from 85 different countries, exploring their preferences...
Journal of Psychoactive Drugs
November 6, 2024
Rotem Petranker, Valentyn Sobolenko, Zeina Beidas et al.
9 citations
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193...
Frontiers in Psychiatry
February 5, 2024
Rotem Petranker, Thomas Anderson, Youval Aberman et al.
14 citations
Introduction The practice of taking small, sub-hallucinogenic doses of psychedelics, known as microdosing, has exploded in popularity over the last decade. Users claim benefits ranging from improved mood and enhanced creativity to an increased sense of meaning and connectedness in life. While research on microdosing is still lagging behind the shift in public opinion, several papers have been...
Frontiers in Psychology
August 9, 2023
Patric Plesa, Rotem Petranker
The resurgence of psychedelic research explicitly targets treating mental health conditions largely through psychedelics-assisted psychotherapy. Current theories about mechanisms of change in psychedelics-assisted psychotherapy focus on mystical experiences as the main driver of symptom improvement. During these mystical experiences, participants report an enhanced sense of salience,...
Psychopharmacology
December 1, 2022
Ido Hartogsohn, Rotem Petranker
22 citations
The use of psychedelics for medical and recreational purposes is rising. Contextual factors such as expectancy, intention, and sensory and social environment (set and setting) are widely recognized as moderating the effects of these substances. Nevertheless, clinical trials of microdosing - the ingestion of small, sub-hallucinogenic doses of psychedelics - rarely report their set and setting....
April 13, 2022
Patric Plesa, Rotem Petranker
3 citations
preprint
A psychedelic industrial complex is emerging as new research on these substances and their effects are being approved. These substances show promise, but much remains unknown about their potential for both benefit and harm. Despite the paucity of reliable mechanistic evidence, some entrepreneurs have already begun to market psychedelic advice. We draw on some critiques of the self-help industry...
Journal of Humanistic Psychology
February 14, 2022
Rotem Petranker, Juensung J. Kim, Thomas Anderson
The use of psychedelic substances in both humanistic and mainstream clinical research has been increasing in the last decade. In particular, the practice of microdosing—ingesting sub-hallucinogenic doses of psychedelics—has been increasing in popularity, but large-scale qualitative analyses are still uncommon. This study attempted to recognize emergent themes in qualitative reports regarding...
Journal of Psychopharmacology
October 8, 2020
Rotem Petranker, Thomas Anderson, Larissa J. Maier et al.
57 citations
Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containing mushrooms. Despite its surging popularity, little is known about the specific intentions to start microdosing and the effects of this practice. Aims: First, we aimed to replicate previous findings regarding the subjective benefits and challenges...
Frontiers in Psychology
July 10, 2020
Rotem Petranker, Thomas Anderson, Norman A. S. Farb
66 citations
Psychedelics have a checkered past, alternately venerated as sacred medicines and vilified as narcotics with no medicinal or research value. After decades of international prohibition, a growing dissatisfaction with conventional mental health care and the pioneering work of the Multidisciplinary Association for Psychedelic Science (MAPS) and others has sparked a new wave of psychedelic...
May 26, 2020
Rotem Petranker, Juensung J. Kim, Thomas Anderson
4 citations
preprint
Background: The use of psychedelic substances like LSD and magic mushrooms in research and to treat mental health conditions has been increasing in the last decade. In particular, the practice of microdosing – using sub-hallucinogenic amounts of psychedelics – has been increasing (Anderson et al., 2019), but large-scale systemic qualitative analyses are still scant.Aims: This study attempted to...
April 12, 2020
Rotem Petranker, Thomas Anderson, Larissa J. Maier et al.
14 citations
preprint
Background: Microdosing psychedelics – the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushrooms – is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. Aims: This research had three main aims. First, we attempted to replicate previous findings regarding the subjective benefits...
Journal of Psychopharmacology
February 28, 2020
Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al.
75 citations
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...
Harm Reduction Journal
July 9, 2019
Thomas Anderson, Rotem Petranker, Adam Christopher et al.
130 citations
These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements...
Psychopharmacology
January 2, 2019
Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al.
171 citations
RationaleMicrodosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties,...